Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study

被引:7
|
作者
Yang, Xiaoqin [1 ]
Yoo, Hyun Kyoo [2 ]
Amin, Suvina [3 ]
Cheng, Wendy Y. [4 ]
Sundaresan, Sanjana [4 ]
Zhang, Lujia [4 ]
Duh, Mei S. [4 ]
机构
[1] Merck & Co Inc, Rahway, NJ 07065 USA
[2] AstraZeneca Rare Dis, Alex, Cambridge, England
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
关键词
Neurofibromatosis type 1; Plexiform neurofibromas; Caregiver burden; Work productivity loss; Activity impairment; Cross-sectional study; Zarit Burden Interview; WPAI; Quality of life; CHILDREN; DISEASE; ADOLESCENTS; MORBIDITY; DISTRESS; FAMILIES; PARENTS; YOUTH;
D O I
10.1007/s40120-022-00365-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Patients with neurofibromatosis type 1 (NF1) may develop plexiform neurofibromas (PNs) that can cause disfigurement, pain, and dysfunction, and may even be life-threatening. Studies have indicated NF1-PN can substantially impact the quality of life (QoL) of pediatric patients. However, research on caregiver burden is scarce. Methods Caregivers of pediatric patients ages 2-18 years with NF1-PN in the USA were recruited through the Children's Tumor Foundation to participate in an online cross-sectional survey (December 2020-January 2021). Caregiver burden was measured using the Zarit Burden Interview (ZBI), and productivity loss from patientcare was measured using the Work Productivity and Activity Impairment questionnaire, adapted for caregiving (WPAI:CG). Results Ninety-five caregivers were recruited with a median age of 44.0 years. Most were female (88.4%), white/Caucasian (85.3%), and did not have NF1 or PN (86.3% and 89.5%, respectively). Commonly reported health conditions among caregivers include anxiety (48.4%) and depression (34.7%). On the ZBI (range 0-88; higher = greater burden), mean (SD) scores were 23.0 (13.8) and 12.7% of caregivers reported moderate-severe (scores 41-60) or severe burden (scores 61-88). Fifty-six caregivers were employed and working in the 7 days prior to completing the WPAI:CG. They reported missing an average of 6.9% of their working hours and an average reduction of 17.3% of on-the-job effectiveness, contributing to 22.3% loss in work productivity. Among all 95 caregivers, an average of 17.2% of regular daily activities were impaired. Conclusions The burden among caregivers of pediatric patients with NF1-PN is considerable and underscores an unmet need for better disease management.
引用
收藏
页码:1221 / 1233
页数:13
相关论文
共 50 条
  • [21] Exploratory Study on the Neurocognitive Phenotype of Pediatric Patients With Moyamoya and Neurofibromatosis Type 1 (NF1)
    Pescatore, S.
    Powell, S.
    Yohay, K.
    Segal, D.
    Lois, B.
    CLINICAL NEUROPSYCHOLOGIST, 2024, 38 (04) : 864 - 865
  • [22] PHASE I TRIAL OF SORAFENIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE I (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Kim, A.
    Dombi, E.
    Tepas, K.
    Fox, E.
    Balis, F. M.
    Korf, B.
    Widemann, B. C.
    NEURO-ONCOLOGY, 2010, 12 (06) : II42 - II42
  • [23] Malignant peripheral nerve sheath tumour (MPNST) arising in plexiform neurofibroma in a neurofibromatosis type I (NF1) patient
    Sykaras, A.
    Gioti, E.
    Stavrinou, N.
    Dolkiras, P.
    Christofidis, K.
    Kouvidou, C.
    VIRCHOWS ARCHIV, 2021, 479 : S307 - S307
  • [24] Cerebral FDG metabolic pattern in pediatric patients with neurofibromatosis type 1 (NF1): A retrospective study
    Vejdani, Kaveh
    Geller, Thomas
    Nghi Nguyen
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [25] High Burden of Deep-Seated Plexiform Neurofibromas (PN) in Children with Neurofibromatosis 1 (NF1): Image-Defined Risk Factors
    Kelaidi, C.
    Petrikkos, L.
    Tzotzola, V. S.
    Antoniadi, K.
    Gavra, M.
    Stefanaki, K.
    Polychronopoulou, S.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S355 - S355
  • [26] Dermatology access for patients with neurofibromatosis type 1 (NF1): a survey study
    Poplausky, Dina
    Orloff, Jeremy
    Piontkowski, Austin J.
    Verma, Hannah
    Silver, Caroline
    Young, Jade N.
    Powers, Camille M.
    Rivera-Oyola, Ryan
    Brown, Rebecca M.
    Gulati, Nicholas
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
  • [27] Characterization of NF1 frameshift mutations in pediatric patients with neurofibromatosis type I
    Villa-Morales, J.
    Lopez-Munoz, E.
    Juarez-Melchor, D.
    Garcia-Hernandez, N.
    Minauro-Sanmiguel, F.
    Aguirre-Hernandez, J.
    Gutierrez-Iglesias, G.
    Arenas-Aranda, D. J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03): : 8326 - 8337
  • [28] Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions
    Kluwe, Lan
    Nguyen, Rosa
    Vogt, Julia
    Bengesser, Kathrin
    Mussotter, Tanja
    Friedrich, Reinhard E.
    Jett, Kimberly
    Kehrer-Sawatzki, Hildegard
    Mautner, Victor-Felix
    GENES CHROMOSOMES & CANCER, 2012, 51 (05): : 447 - 451
  • [29] TOLERABILITY OF THE MTOR INHIBITOR SIROLIMUS IN A PHASE II STUDY FOR NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A NEUROFIBROMATOSIS CONSORTIUM STUDY
    Weiss, B.
    Widemann, B. C.
    Cantor, A.
    Perentesis, J.
    Vinks, A.
    Ullrich, N.
    Gutmann, D.
    Korp, B.
    Packer, R.
    Fisher, M. J.
    NEURO-ONCOLOGY, 2010, 12 (06) : II85 - II85
  • [30] Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study
    Siegel, Atara
    Lockridge, Robin
    Struemph, Kari L.
    Toledo-Tamula, Mary Anne
    Little, Paige
    Wolters, Pamela L.
    Dufek, Anne
    Tibery, Cecilia
    Baker, Melissa
    Wideman, Brigitte C.
    Martin, Staci
    JOURNAL OF PEDIATRIC PSYCHOLOGY, 2024, 49 (06) : 383 - 391